


Don't Fight a Well-Armed Feisty Fed

- **The Fed has gone “all-out” but markets remain doubtful.** The decision to link the degree of monetary stimulus directly to the key measure of capacity utilisation (unemployment) is as aggressive as we have ever seen from the Fed. History shows that it has always been wrong to “fight the Fed” once it has decided to use whatever monetary stimulus is necessary to rectify a below capacity economy. Yet consensus expectations for US growth remaining at or below potential, alongside pervasive doubts about the efficacy of QE, indicate that the equity market is doubting the Fed’s ability to succeed this time. On the one hand there are worries that efforts to create “artificially” low interest rates will lead to an inflation shock. On the other hand there are worries that in a “zero bound” deflationary world, the Fed has run out of “ammunition” and is therefore “pushing on a string”, with QE only providing a temporary boost to asset prices and failing to stimulate the economy. So the question as to whether QE works has now become of paramount importance in considering the outlook for equity markets.
- **Interest rates are not artificially low, they are naturally low** and the very depressed level of bond yields in most of the major economies reflects market forces more so than central bank buying (Chart 1). Notions of “financial repression” and the inflationary consequences of an unusually low real Fed funds rate look to be well overdone. The Fed’s job is not to pick an interest rate out of the air or to rob savers of a “fair return” but rather to set its official interest rate at the level that reflects the natural clearing rate that equilibrates desired savings and desired investment in the economy at any particular point in time, thus promoting full employment and price stability. In an environment where structural factors had already been dictating an unusually low clearing level for global interest rates, it makes sense to believe that the additional downward cyclical pressure on rates in the aftermath of one of the biggest ever economic downturns could justify a real Fed funds rate well into negative territory. Failure to deliver an appropriately low rate would amount to deflationary policy error and inflationary policy error would only occur if the real rate is kept inappropriately low as the economy moves back towards a more normal level of unemployment.
- **The essence of monetary policy has always been about controlling the real “risk free” rate and nothing has changed in this regard.** Until the recent downturn, the Fed had always been able to do this by adjusting the nominal level of its official interest rate to achieve the appropriate real level. However, the co-existence in recent years of structurally low inflation alongside a structurally (and cyclically) very low level for the natural interest rate has created the “zero bound” problem whereby the Fed’s technical inability to push its nominal official rate below zero means that it loses its ability to control the all-important real rate to the downside once the zero nominal limit is reached. Once the zero bound is reached, the only way for the Fed to maintain downside control over the real official interest rate is through its ability to manage inflation expectations to the upside.
- **The essential purpose of QE is to manage inflation expectations to the level required to achieve the appropriate level of the real Fed funds rate when the zero bound for the nominal rate has been reached.** So, the answer to the question as to whether QE works is dependent on whether QE allows the Fed to control inflation expectations. All the evidence suggests that the Fed has been able to boost inflation expectations at will through its use of QE while also keeping such expectations on a rising track over recent years (Chart 2). So, although the nominal Fed funds rate has been flat-lining over recent years at the zero bound, the Fed has been able to manage the all-important real Fed funds rate lower (Chart 3). QE is often portrayed as an ineffective drug inducing only temporary relief and requiring bigger and bigger doses for shorter and shorter remission. However the analogy of a lifesaving medicine for which the dosage is still being perfected seems more appropriate.

Bernard Mc Alinden, 00 353 (0)87 241 4826, Bernard.mcalinden@esnpartnership.eu
Kate O’Dowd, 00 353 (0)1 611 5845, kate.odowd@esnpartnership.eu

- **The balance of evidence already suggests that QE has in fact been working.** “Taylor rule” calculations are showing that whereas QE1 and QE2 etc. were entirely justified, the deflationary threat has already been largely seen off and that the current 0.25% nominal level of the Fed funds rate is now just about appropriate with no need for more QE to further boost inflation expectations (Chart 4). However, with the outlook for Eurozone and China increasingly clouded and with the local risk of inappropriate deflationary political deadlock in respect of the “fiscal cliff”, the Fed remains on standby to make monetary policy yet looser, through pushing inflation expectations higher (while extending its commitment to a zero-based nominal rate), should the labour market fail to make satisfactory progress.
- **It makes sense for the Fed to play down the 2% inflation target while not abandoning it.** With the nominal Fed funds rate effectively zero-bound at 0.25%, market perceptions of a strict 2% inflation target (and related 2% inflation expectation) become problematic whenever the Fed judges that the appropriate level for the real Fed funds rate is lower than minus 1.75%. With 5-year inflation expectations currently around 2.2%, the real Fed funds rate is effectively in the region of minus 1.95% now. The Fed is practicing the art of maintaining enough “wriggle room” to maintain downside control of the real Fed funds rate through manipulation of inflation expectations (say between 2% and 3%), while at the same time not undermining its longer term inflation fighting credentials.
- **The Fed is leading global monetary policy** and other central banks like the ECB and the BOJ must inevitably follow or suffer inappropriate deflationary currency strength against the Dollar.
- **It is not different this time.** QE works. The Fed is fully committed and is not out of ammunition. The Fed is underwriting the ongoing global economic expansion and the related ongoing global cyclical bull market in equities (save for the impact of any unforeseeable geopolitical events). Don’t fight a well-armed and feisty Fed.


Chart 1: Market forces have been driving real interest rates downwards



Source: Bloomberg, ESN


Strategy Flashnote

Chart 2: Controlling inflation expectations is Fed's main weapon in a 'zero bound' world




Source: Bloomberg, ESN

Chart 3: Fed is still in control of the 'Real' Fed Funds Rate



Source: Bloomberg, ESN

Chart 4: Q.E. has been working



Source: Bloomberg, ESN

ESN Recommendation system

The ESN Recommendation System is **Absolute**. It means that each stock is rated on the basis of a **total return**, measured by the upside potential (including dividends and capital reimbursement) over a **12 month time horizon**.


The ESN spectrum of recommendations (or ratings) for each stock comprises 5 categories: **Buy, Accumulate (or Add), Hold, Reduce and Sell (in short: B, A, H, R, S)**.

Furthermore, in specific cases and for a limited period of time, the analysts are allowed to rate the stocks as **Rating Suspended (RS)** or **Not Rated (NR)**, as explained below.

Meaning of each recommendation or rating:

- **Buy:** the stock is expected to generate total return of **over 20%** during the next 12 months time horizon
- **Accumulate:** the stock is expected to generate total return of **10% to 20%** during the next 12 months time horizon
- **Hold:** the stock is expected to generate total return of **0% to 10%** during the next 12 months time horizon.
- **Reduce:** the stock is expected to generate total return of **0% to -10%** during the next 12 months time horizon
- **Sell:** the stock is expected to generate total return **under -10%** during the next 12 months time horizon
- **Rating Suspended:** the rating is suspended due to a capital operation (take-over bid, SPO, ...) where the issuer of the document (a partner of ESN) or a related party of the issuer is or could be involved or to a change of analyst covering the stock
- **Not Rated:** there is no rating for a company being floated (IPO) by the issuer of the document (a partner of ESN) or a related party of the issuer

ESN Ratings Breakdown




History of ESN Recommendation System

Since **18 October 2004**, the Members of ESN are using an Absolute Recommendation System (before was a Relative Rec. System) to rate any single stock under coverage.

Since **4 August 2008**, the ESN Rec. System has been amended as follow.

- Time horizon changed to 12 months (it was 6 months)
- Recommendations Total Return Range changed as below:



Disclaimer:

These reports have been prepared and issued by the Members of European Securities Network LLP ("ESN"). ESN, its Members and their affiliates (and any director, officer or employee thereof), are neither liable for the proper and complete transmission of these reports nor for any delay in their receipt. Any unauthorised use, disclosure, copying, distribution, or taking of any action in reliance on these reports is strictly prohibited. The views and expressions in the reports are expressions of opinion and are given in good faith, but are subject to change without notice. These reports may not be reproduced in whole or in part or passed to third parties without permission. The information herein was obtained from various sources. ESN, its Members and their affiliates (and any director, officer or employee thereof) do not guarantee their accuracy or completeness, and neither ESN, nor its Members, nor its Members' affiliates (nor any director, officer or employee thereof) shall be liable in respect of any errors or omissions or for any losses or consequential losses arising from such errors or omissions. Neither the information contained in these reports nor any opinion expressed constitutes an offer, or an invitation to make an offer, to buy or sell any securities or any options, futures or other derivatives related to such securities ("related investments"). These reports are prepared for the clients of the Members of ESN only. They do not have regard to the specific investment objectives, financial situation and the particular needs of any specific person who may receive any of these reports. Investors should seek financial advice regarding the appropriateness of investing in any securities or investment strategies discussed or recommended in these reports and should understand that statements regarding future prospects may not be realised. Investors should note that income from such securities, if any, may fluctuate and that each security's price or value may rise or fall. Accordingly, investors may receive back less than originally invested. Past performance is not necessarily a guide to future performance. Foreign currency rates of exchange may adversely affect the value, price or income of any security or related investment mentioned in these reports. In addition, investors in securities such as ADRs, whose value are influenced by the currency of the underlying security, effectively assume currency risk.

ESN, its Members and their affiliates may submit a pre-publication draft (without mentioning neither the recommendation nor the target price/fair value) of its reports for review to the Investor Relations Department of the issuer forming the subject of the report, solely for the purpose of correcting any inadvertent material inaccuracies. Like all members employees, analysts receive compensation that is impacted by overall firm profitability. For further details about the specific risks of the company and about the valuation methods used to determine the price targets included in this report/note, please refer to the latest relevant published research on single stock or contact the analyst named on the front of the report/note. Research is available through your sales representative. ESN will provide periodic updates on companies or sectors based on company-specific developments or announcements, market conditions or any other publicly available information. Unless agreed in writing with an ESN Member, this research is intended solely for internal use by the recipient. Neither this document nor any copy of it may be taken or transmitted into Australia, Canada or Japan or distributed, directly or indirectly, in Australia, Canada or Japan or to any resident thereof. This document is for distribution in the U.K. Only to persons who have professional experience in matters relating to investments and fall within article 19(5) of the financial services and markets act 2000 (financial promotion) order 2005 (the "order") or (ii) are persons falling within article 49(2)(a) to (d) of the order, namely high net worth companies, unincorporated associations etc (all such persons together being referred to as "relevant persons"). This document must not be acted on or relied upon by persons who are not relevant persons. Any investment or investment activity to which this document relates is available only to relevant persons and will be engaged in only with relevant persons.

The distribution of this document in other jurisdictions or to residents of other jurisdictions may also be restricted by law, and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. By accepting this report you agree to be bound by the foregoing instructions. You shall indemnify ESN, its Members and their affiliates (and any director, officer or employee thereof) against any damages, claims, losses, and detriments resulting from or in connection with the unauthorized use of this document.

For disclosure upon "conflicts of interest" on the companies under coverage by all the ESN Members and on each "company recommendation history", please visit the ESN website (www.esnpartnership.eu). For additional information and individual disclaimer please refer to www.esnpartnership.eu and to each ESN Member websites:

www.bancaakros.it regulated by the CONSOB - Commissione Nazionale per le Società e la Borsa

www.bankiabolosa.es regulated by CNMV - Comisión Nacional del Mercado de Valores

www.caixabi.pt regulated by the CMVM - Comissão do Mercado de Valores Mobiliários

www.cmcics.com regulated by the AMF - Autorité des marchés financiers

www.degroof.be regulated by the FSMA - Financial Services and Markets Authority

www.equinet-aq.de regulated by the BaFin - Bundesanstalt für Finanzdienstleistungsaufsicht

www.ibg.gr regulated by the HCMC - Hellenic Capital Market Commission

www.ncb.ie regulated by the Central Bank of Ireland

www.pohjola.com regulated by the Financial Supervision Authority

www.snssecurities.nl regulated by the AFM - Autoriteit Financiële Markten

Members of ESN (European Securities Network LLP)



Banca Akros S.p.A.
Viale Eginardo, 29
20149 Milano
Italy
Phone: +39 02 43 444 389
Fax: +39 02 43 444 302



Equinet Bank AG
Gräfstraße 97
60487 Frankfurt am Main
Germany
Phone: +49 69 – 58997 – 410
Fax: +49 69 – 58997 – 299



Bank Degroof
Rue de l'Industrie 44
1040 Brussels
Belgium
Phone: +32 2 287 91 16
Fax: +32 2 231 09 04



Investment Bank of Greece
24B, Kifisias Avenue
151 25 Marousi
Greece
Phone: +30 210 81 73 000
Fax: +30 210 68 96 325



Bankia Bolsa
Serrano, 39
28001 Madrid
Spain
Phone: +34 91 436 7813
Fax: +34 91 577 3770



NCB Stockbrokers Ltd.
3 George Dock,
Dublin 1
Ireland
Phone: +353 1 611 5611
Fax: +353 1 611 5781



Caixa-Banco de Investimento
Rua Barata Salgueiro, 33-5
1269-050 Lisboa
Portugal
Phone: +351 21 389 68 00
Fax: +351 21 389 68 98



Pohjola Bank plc
P.O.Box 308
FI-00013 Pohjola
Finland
Phone: +358 10 252 011
Fax: +358 10 252 2703



CM - CIC Securities
6, avenue de Provence
75441 Paris
Cedex 09
France
Phone: +33 1 4596 7940
Fax: +33 1 4596 7748



SNS Securities N.V.
Nieuwezijds Voorburgwal 162
P.O.Box 235
1000 AE Amsterdam
The Netherlands
Phone: +31 20 550 8500
Fax: +31 20 626 8064

